Hot off the press! The CameL study reveals a 5-year overall survival rate of 31.2%,unveiled at ELCC!
Camrelizumab contributes to longer survival for advanced lung cancer patients.
The 5-year long-term follow-up results of the randomized, open-label, multicenter, phase III clinical trial (CameL Study): Camrelizumab in combination with carboplatin and pemetrexed versus chemotherapy in first-line treatment for advanced EGFR/ALK gene-negative Non-Squamous Non-Small Cell Lung Cancer (NSCLC)," led by professor Caicun Zhou from Shanghai Pulmonary Hospital, were announced at the European Lung Cancer Congress (ELCC) held in Prague, Czech Republic from March 20th to 23rd, 2024.
The latest survival data shows that the 5-year overall survival (OS) rate for advanced EFGR/ALK gene-negative non-squamous non-small cell lung cancer (NSCLC) treated with camrelizumab in combination with chemotherapy in the first-line is 31.2% (compared to 19.3% in the chemotherapy group), contributing to longer survival for more patients. The 5-year progression-free survival (PFS) rate is 16.1%, significantly controlling disease progression in patients.
Picture from: Global Release Conference of the 5-Year Overall Survival Results from CameL Study.
The 5-year overall survival or 5-year survival rate is a crucial metric in assessing clinical outcomes and potential cures for cancer. Camrelizumab stands out as the only immunotherapy drug in China with 5-year survival data available for NSCLC patients. This signifies that in this study, nearly one-third of the patients have achieved survival beyond five years. This accomplishment reflects yet another positive contribution by Jiangsu Hengrui Medicine, representing China's pharmaceutical innovation, towards improving survival rates for cancer patients.
blog comments powered by